8-K current report · filed Nov 20, 2026

Boston Scientific (BSX) 8-K Current Report: November 20, 2026

Item 1.01Item 2.03Item 8.01Item EX-99.1BSX overview

Short answer

Boston Scientific (BSX) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $3.0B USD notes and €4.25B euro notes priced November 19, 2026, with expected closing December 1, 2026.

Boston Scientific 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $3.0B USD notes and €4.25B euro notes priced November 19, 2026, with expected closing December 1, 2026
  • Fixed-rate coupons range from 5.375% to 5.875% on USD notes, maturing 2029-2036
  • Euro notes mature 2028-2046, with fixed coupons of 3.875%-5.125% plus €500M floating-rate notes
  • Proceeds primarily fund cash consideration for the Penumbra acquisition, increasing debt financing and interest obligations
  • Failure to complete Penumbra by the applicable outside date triggers redemption of most notes at 101% plus accrued interest

Item 8.01 · Other Events

  • November 19, 2026 press release announces the material event described in the 8-K
  • Exhibit 99.1 contains the substantive details investors need to assess the event’s impact on Boston Scientific

Item EX-99.1 · Exhibit EX-99.1

  • $3.0B USD and €4.25B euro senior-note offerings priced, substantially expanding debt funding
  • Coupon structure: USD notes 5.375%-5.875% due 2029-2036, euro notes 3.875%-5.125% due 2028-2046
  • Proceeds primarily financing Penumbra acquisition cash consideration, fees and expenses
  • Offerings expected to close December 1, 2026, independently of acquisition completion
  • If Penumbra transaction fails by applicable deadline, mandatory redemption at 101% plus accrued interest, limiting but not eliminating financing risk

Other items in this filing:

  • Item 2.03: Creation of a Direct Financial Obligation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Boston Scientific 8-K filings

Get the next BSX 8-K as it lands

Follow BSX for push alerts, or ask the research agent what this filing means.